- ¥138bn
- ¥128bn
- ¥40bn
Annual cashflow statement for Takara Bio, fiscal year end - March 31st, JPY millions except per share, conversion factor applied.
2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | 2026 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | Yuho | Yuho | Yuho | Yuho | Tanshin |
| Standards: | JAS | JAS | JAS | JAS | — |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | 27,532 | 21,224 | 2,853 | 1,997 | -9,200 |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | 473 | -479 | 293 | 485 | 4,034 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -25,074 | 11,502 | -6,353 | -939 | 3,644 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Accounts Payable | |||||
| Change in Taxes Payable | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | 6,985 | 36,896 | 1,712 | 5,844 | 3,631 |
| Capital Expenditures | -12,539 | -5,882 | -12,872 | -10,278 | -12,599 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 5,468 | -811 | -171 | -634 | -6,081 |
| Acquisition of Business | |||||
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -7,071 | -6,693 | -13,043 | -10,912 | -18,680 |
| Financing Cash Flow Items | — | — | — | 0 | -1,567 |
| Other Financing Cash Flow | |||||
| Total Cash Dividends Paid | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -2,070 | -4,119 | -5,233 | -2,256 | 6,121 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -1,148 | 26,897 | -15,886 | -6,134 | -8,824 |